Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses

Phio Pharmaceuticals Corp.

18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.
cSCC responses: 6 complete (100% clearance), 2 near complete (>90%), 2 partial (>50%).
Merkel cell patient had partial response (>50% clearance); no patients showed disease progression.
No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.
Highest dose cohort still enrolling; pathology results expected Q1 2026.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.